

Day 1, Thursday 18 September, 12:30–19:00

TIME	SESSION	SPEAKER(S)
12:00	Registration opens	
12:30–12:40	Welcome	Deepti Radia & Clive Grattan
12:40–13:00	Welcome and introduction <ul style="list-style-type: none"> • Status of the ECNM • Presentation of Researcher of the Year award 	Peter Valent & Massimo Triggiani
13:00–13:40	Utility and application of KIT mutations and other molecular markers in mast cell neoplasms	Michel Arock
13:40–14:00	Afternoon coffee break	
14:00–15:00	SESSION 1: Updates in pathology and classification <ul style="list-style-type: none"> • Harmonisation of the EU/US, ICC and WHO classification of mastocytosis • Application of ICC and WHO criteria by the pathologist • Histopathological and phenotypic changes of mast cells during TKI therapy • Rare cases and histopathological patterns in SM-AHN 	Chaired by Wolfgang R Sperr & Karl Sotlar Peter Valent Karl Sotlar Tracy George Hans Peter Horny
15:00–15:30	Afternoon coffee break	
15:30–16:45	SESSION 2: Updates in paediatric and adult dermatological presentations of mast cell disease <ul style="list-style-type: none"> • Diagnosis and management of skin problems in paediatric mastocytosis • Quantification of skin disease in CM and SM during therapy • Therapy of cutaneous disease in pediatric CM • Phototherapy and photochemotherapy in CM and SM • Challenges and potential shortfalls in current classification of cutaneous mastocytosis 	Chaired by Magdalena Lange & Vito Sabato Melody Carter Karin Hartmann Magdalena Lange Valeria Brazzelli & Iván Álvarez-Twose
16:45–17:15	Afternoon coffee break	
17:15–18:15	SESSION 3: Comorbidities in mastocytosis <ul style="list-style-type: none"> • Bone health and disease management in patients with SM • Drug reactions and food intolerance in mastocytosis • Causes of death in patients with mastocytosis: Impact of comorbidities • IgE-dependent allergies in mastocytosis 	Chaired by Knut Brockow & Massimo Triggiani Massimo Triggiani Mariana Castells Axel Rüfer Hanneke Oude Elberink
18:15–18:55	Keynote lecture 1: Mast cells and basophils in allergeo-oncology: bridging allergy to cancer	Introduced by Clive Grattan Sophia Karagiannis
18:55–19:00	Summary of Day 1 and announcements	

Drinks reception at the Park Plaza London Riverbank Hotel from 19:30–20:30

TIME	SESSION	SPEAKER(S)
08:30	Welcome and registration	
09:00–10:00	SESSION 4: ECNM Registry Projects – Part 1	Chaired by Wolfgang R Sperr & Michel Arock
	<ul style="list-style-type: none"> Overview of ECNM registry projects Highlights in W1 through W8 projects PR1: Analysis of various age groups PR14: Body mass index in mastocytosis PR18: Pure CM in adults 	Wolfgang R. Sperr Peter Valent Karin Hartmann Marek Niedoszytko Knut Brockow
10:00–10:20	<i>Morning coffee break</i>	
10:20–11:00	SESSION 4: ECNM Registry Projects – Part 2	Chaired by Wolfgang R Sperr & Michel Arock
	<ul style="list-style-type: none"> PR19: AHN: Frequency of subtypes and prognosis PR42: Clinical impact of KITD816V VAF in SM PR45: Causes of death in non-advanced SM Overview of new projects and EU grant application 	Olivier Hermine Frank Siebenhaar Axel Rüfer & Theo Gülen Peter Valent
11:00–11:15	<i>Morning coffee break</i>	
11:15–12:00	SESSION SATELLITE MEETING – CLINICAL SCENARIOS	
12:00–12:50	<i>Lunch break and poster sessions</i>	
12:50–13:00	Group photo	
13:00–13:45	Keynote lecture 2:	Introduced by Peter Valent
	Molecular studies in mastocytosis and AHN, and use of AI tools	Gregor Hörmann
13:45–15:00	SESSION 5: Diagnostic challenges in mastocytosis	Chaired by Iván Álvarez-Twose & Karin Hartmann
	<ul style="list-style-type: none"> Lab features and flow cytometry correlates with clinical phenotypes I think I have the mast cell HaT and implications in clinical practice Early phases and pre-phases of mast cell neoplasms Classification of pre-SM conditions and development of prevention strategies 	Alberto Orfao Clive Grattan Jonathan Lyons Olivier Hermine Peter Valent
15:00–15:25	<i>Afternoon coffee break</i>	
15:25–16:40	SESSION 6: Anaphylaxis and mast cell activation syndrome	Chaired by Jens Peter Panse & Hanneke Oude Elberink
	<ul style="list-style-type: none"> Why we have mast cells: The venom interception theory How to manage false-positive MCAS and its mimickers Diagnosis and management of MCAS Immunotherapy in mastocytosis Long- or short-term Hymenoptera venom immunotherapy in mastocytosis? 	Stephen Galli Theo Gulen Cem Akin Marek Niedoszytko Patrizia Bonadonna
16:40–17:10	<i>Afternoon coffee break</i>	
17:10–18:25	SESSION 7: Translational and real-world research in mastocytosis	Chaired by Sigurd Broesby-Olsen & Marek Niedoszytko
	<ul style="list-style-type: none"> Which biomarkers are useful in mast cell activation? Detection of KIT variants in blood and skin of patients with mastocytosis Tryptase: From bench to clinical use in applied haematology Biology of tryptase and application in practice Tryptase as a screening parameter in paediatric mastocytosis 	Gunnar Nilsson Sigurd Broesby-Olsen Wolfgang R. Sperr Lawrence B. Schwartz Knut Brockow
18:25–18:30	Summary of Day 2 and announcements	

Day 3, Saturday 20 September, 08:00–15:00

TIME	SESSION	SPEAKER(S)
08:00	Welcome and registration	
08:30–09:30	SESSION 8: Prognostication and efficacy of novel TKIs in SM <ul style="list-style-type: none"> Development of MARS-R Efficacy of recently approved and novel TKIs in SM clinical practice Real-world data of avapritinib-treated patients with ISM Diagnosis, prognostication and therapy of WDSM 	Chaired by Tracy George & Juliana Schwaab Johannes Lübke Juliana Schwaab Frank Siebenhaar Iván Álvarez-Twose
09:30–10:00	Morning coffee break	
10:00–12:00	SESSION 9: Invited presentations and late-breaking abstracts	Chaired by Deepti Radia & Jason Gotlib
12:00–13:00	Lunch break and poster sessions	
13:00–14:15	SESSION 10: Updates in management of advanced and non-advanced systemic mastocytosis – looking forwards <ul style="list-style-type: none"> Non-advanced SM landscape: TKIs Non-advanced SM landscape: non-TKIs Mutational landscape changing the paradigm for treatment Advanced SM landscape and complete remission and cure: The new goal in patients with advanced SM: Status 2025 Role of allogeneic BMT 	Chaired by Frank Siebenhaar & Peter Valent Cem Akin Vito Sabato Andreas Reiter Jason Gotlib Deepti Radia
14:15–14:30	Summary of Day 3 and closing remarks	Peter Valent, Massimo Triggiani, Deepti Radia & Clive Grattan

International patient forum with roundtable discussion at the Park Plaza London Riverbank Hotel from 16:30–18:30